Saturday, November 18, 2023
Today, BIOVECTRA is celebrating the successful completion of its ambitious $90 million-plus biologics expansion project at the new Biomanufacturing Centre. The venture, undertaken in collaboration with the Government of Canada and the Government of Prince Edward Island, positions BIOVECTRA at the forefront of advancing treatments for rare and incurable diseases and contributing to the production of vaccines for future pandemics, according to CEO Oliver Technow.
The 18-month timeline, from groundbreaking to completion, underscores the rapid pace of BIOVECTRA's expansion, which enhances Canada's role in the global effort to provide the next generation of patient care through mRNA vaccines and therapeutics. The company's specialized capabilities in mRNA, pDNA, lipid nanoparticle, and fill/finish work are the first of their kind in Canada, representing a significant milestone in the country's strategy for better health crisis preparedness.
The grand opening of BIOVECTRA's state-of-the-art facility strengthens Atlantic Canada's position as a hub for biomanufacturing and life sciences. The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, highlighted the government's role in supporting the project, emphasizing its contribution to Canada's global leadership in the sector and the creation of well-paying jobs.
BIOVECTRA's expansion into mRNA vaccines and therapeutics on Prince Edward Island's global standing in drug therapeutics manufacturing. The initiative is expected to make cutting-edge treatments accessible to Islanders, Canadians, and global citizens, with positive ripple effects on PEI's health, education, and labor market sectors.
Globally, mRNA and pDNA products are emerging as the next generation of solutions for improved patient care. BIOVECTRA's capabilities, spanning from research discovery to final commercial vials, position the company to support a diverse range of clients, from biotech start-ups to established pharmaceutical companies, from its operations in Atlantic Canada.